Coffee and Amyotrophic Lateral Sclerosis: A Possible Preventive Role by Beghi E, Pupillo E & For, the EURALS Group
American Journal of Epidemiology
ª The Author 2011. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of
Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
DOI: 10.1093/aje/kwr229
Original Contribution
Coffee and Amyotrophic Lateral Sclerosis: A Possible Preventive Role
Ettore Beghi*, Elisabetta Pupillo, Paolo Messina, Giorgia Giussani, Adriano Chio`,
Stefano Zoccolella, Cristina Moglia, Massimo Corbo, and Giancarlo Logroscino for the EURALS
5 Group
* Correspondence to Dr. Ettore Beghi, Laboratory of Neurological Disorders, ‘‘Mario Negri’’ Institute, Via G. la Masa 19, 20156
Milano, Italy (e-mail: ettore.beghi@marionegri.it).
Initially submitted November 19, 2010; accepted for publication June 3, 2011.
The relation between coffee intake and risk of amyotrophic lateral sclerosis (ALS) was investigated in 377 newly
10 diagnosed ALS patients from 4 Italian population-based registries in the European ALS Consortium (EURALS
Group) (2007–2010). For each patient, 2 age- and sex-matched hospital controls were selected, one from a neu-
rology department and one from a nonneurologic department. Two additional healthy control groups were identified
from local general practitioners’ (GPs’) lists (n¼ 99) and residents of the same area as a cancer cohort (n¼ 7,057).
Coffee intake was defined in terms of status (ever consuming coffee daily for 6 months vs. never), duration, and
15 history (never, former, or current). Ever coffee drinkers comprised 74.7% of ALS patients, 80.4% of neurologic
controls, 85.6% of nonneurologic controls (P ¼ 0.0004), 88.9% of GP controls (P ¼ 0.0038), and 86.0% of cancer
cohort controls (P < 0.0001). Current coffee drinkers comprised 60.2% of ALS patients, 70.2% of neurologic
controls (P ¼ 0.0294), 76.4% of nonneurologic controls (P < 0.0001), and 82.3% of GP controls (P ¼ 0.0002);
duration of intake was 30 years for 62.3%, 67.7%, 74.7%, and 72.6%. ALS patients had lower lifetime coffee
20 exposure: Odds ratios were 0.7 (95% confidence interval (CI): 0.5, 1.1), 0.6 (95%CI: 0.4, 0.8), and 0.4 (95%CI: 0.2,
0.9) in comparison with neurologic, nonneurologic, and GP controls, respectively. In current (vs. never) coffee
drinkers, odds ratios were 0.7 (95% CI: 0.5, 1.0), 0.5 (95% CI: 0.3, 0.7), and 0.4 (95% CI: 0.2, 0.8), respectively.
These findings provide epidemiologic evidence of an inverse correlation between coffee intake and ALS risk.
amyotrophic lateral sclerosis; coffee; motor neuron disease
Abbreviations: ALS, amyotrophic lateral sclerosis; EURALS Group, European ALS Consortium; GP, general practitioner.
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Amyotrophic lateral sclerosis (ALS) is a rare, severe
neurologic disorder causing motor neuron degeneration and
death within 3–5 years of symptom onset in approximately
80% of patients (1). Although results of several epidemiologic
30 studies have been reported, no environmental factors or spe-
cific occupations have been consistently found to be associated
with motor neuron loss, with the exception of exposure to
pesticides (2–4). Small sample sizes and differences in study
design may explain the contrasting and mostly negative find-
35 ings. Therefore, we designed a case-control study of newly
diagnosed ALS patients from 4 Italian population-based
registries participating in the European ALS Consortium
(EURALS Group) (5). The aim was to assess the role of
traumatic events and other environmental agents as risk factors
40for ALS. While assessing the independent role of trauma and
adjusting for possible confounders, including age, sex, phys-
ical activity, alcohol drinking, smoking, and coffee intake, we
detected an inverse association between coffee consumption
and risk of ALS.
45MATERIALS AND METHODS
The study population included patients with newly diag-
nosed ALS enrolled in population-based registries in 4 admin-
istrative regions of Italy (Lombardia, Piemonte and Valle
D’Aosta, Puglia, and Liguria; total population¼ 19,997,078
50in the 2009 Italian census) from September 2007 through
1
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April 2010. Patients were aged 18 years or older and had to
fit one of the categories of the El Escorial diagnostic classifi-
cation (‘‘definite,’’ ‘‘probable,’’ or ‘‘possible’’ ALS) (6). Every
patient had to be a resident of the study area. For each patient,
55 2 age- (65 years) and sex-matched hospital controls were
selected. The first control was chosen from a neurology de-
partment and the second from a nonneurologic department.
Patients with neurodegenerative disorders or clinical condi-
tions related to trauma or orthopedic illnesses were excluded.
60 We also tried to match cases and controls by source of inter-
view (patient or surrogate). Informed surrogates were chosen
for patients who were unable to answer or unaware of their
clinical condition and for their matched controls.
After giving informed consent, each case and control (or
65 surrogate) was interviewed by a trained investigator, and ad
hoc semistructured forms were used to collect the following
data: date of enrollment, sex, date of birth, marital status,
education, occupation, physical exercise, family history
of ALS and other neurodegenerative disorders, El Escorial
70 diagnostic category, site of onset of symptoms (bulbar, limbs,
respiratory, or generalized), disease duration at diagnosis,
and functional impairment, measured with the Revised
Amyotrophic Lateral Sclerosis Functional Rating Scale (7).
A detailed history of traumatic events was collected as per
75 study protocol. Tobacco, coffee, and alcohol were chosen as
confounders. Overall coffee intake was assessed as daily con-
sumption for at least 6 months during the participant’s entire
lifetime (ever vs. never), duration of exposure (in years), and
history of consumption (never, former, or current). Tobacco
80 and alcohol intake were assessed similarly and dichotomized
as ever versus never.
The study was considered complete after enrollment of at
least 410 cases and 819 controls under the assumption that
1% of controls would report at least 1 traumatic event re-
85 quiring hospitalization as compared with 3.9% of ALS patients
(odds ratio ¼ 3.9), with a 5% significance level and 80%
power. The study also had sufficient statistical power to detect
a 5-fold increase in ALS risk due to trauma, through recruit-
ment of at least 244 ALS cases and 488 matched controls.
90 Because the 2 control populations were not representative
samples of the general population, 2 additional groups were
identified for comparison. The first group (defined as the ‘‘GP
control group’’) comprised persons recruited from general
practitioners’ (GPs’) lists and chosen as population controls
95 in a parallel case-control study, which is currently exploring
the association between ALS, physical activity, trauma, and
sports. The second group (defined as the ‘‘cancer control
group’’) included healthy Italians residing in the same geo-
graphic area as a cohort of patients with cancer of the colon
100 or rectum (8).
The recorded information was transferred from the forms
into a World Wide Web database and centralized for analysis.
We conducted univariate and multivariate analyses using
conventional parametric tests, as appropriate. Data are pre-
105 sented as percentages and as odds ratios with 95% confidence
intervals. Multivariate analysis was conducted using 3 dif-
ferent logistic regression models to assess the effects of the
3 separate aspects of coffee consumption: 1) status (daily
consumption for 6 months; ever vs. never); 2) duration of
110 coffee consumption (0, 0.5–30, 31–50, or>50 years); and 3)
history (never, former, or current consumption). We conducted
separate analyses for each control group: univariate anal-
ysis (comparing ALS cases with neurologic controls, non-
neurologic controls, GP controls, and cancer controls) and
115multivariate analysis (comparing ALS cases with neurologic
controls, nonneurologic controls, and GP controls) using lo-
gistic regression models. In each model, data were adjusted
for age, sex, education, physical activity, smoking, alcohol
intake, and interviewee (patient/control or surrogate).
120Data were analyzed using the SAS software package for
personal computers, version 9.1 (SAS Institute, Inc., Cary,
North Carolina). The study was approved by the institutional
review board of each center.
RESULTS
125A total of 458 ALS patients and 820 controls (413 neuro-
logic, 407 nonneurologic) were recruited. Eighty-one cases
and 66 controls were later excluded, for the following reasons:
1) empty questionnaires (52 cases, 28 controls); 2) duplicate
input (14 cases, 28 controls); 3) suspected ALS as an El
130Escorial diagnostic category (8 cases, 8 controls); 4) resi-
dency outside of the study area (3 cases, 2 controls); and
5) unavailable matched controls (4 cases).
Table 1 shows the main characteristics of the study sample.
The ALS patients included 146 women and 231 men aged
13527–89 years. The age range of the controls was 29–94 years
for neurologic controls and 26–90 years for nonneurologic
controls. The median age of the cases was 67 years, that
of neurologic controls was 68 years, and that of nonneuro-
logic controls was 67 years. The median numbers of years
140of education were 8 (range, 0–28), 8 (range, 0–26), and
8 (range, 0–25), respectively. The GP control group com-
prised 99 people aged 32–85 years (median, 64 years) with
3–22 years of education (median, 10). Subjects in the cancer
control group were aged 19–79 years (median, 57 years).
145The proportion of smokers was significantly lower in the
ALS group than in neurologic controls, nonneurologic con-
trols (P ¼ 0.0492), the GP control group, and the cancer
control group (P ¼ 0.0003) (Table 1). Physical exercise was
also less frequent among ALS cases. Alcohol consumption
150levels were similar for patients with ALS and neurologic con-
trols but lower for ALS cases than for nonneurologic controls
(P ¼ 0.0056). An informed surrogate was interviewed on be-
half of one-quarter of ALS patients but fewer neurologic con-
trols (P ¼ 0.0217) and nonneurologic controls (P < 0.0100).
155Proxies were almost exclusively spouses and offspring.
There were significantly fewer coffee drinkers among ALS
patients than among nonneurologic controls (P ¼ 0.0004),
GP controls (P ¼ 0.0038), or cancer controls (P < 0.0001)
(Table 2). The proportion of current coffee drinkers was 60.2%
160among ALS cases but somewhat higher among neurologic
controls (P¼ 0.0294), nonneurologic controls (P< 0.0001),
and GP controls (P ¼ 0.0002) (Table 2). Duration of coffee
intake was 30 years or longer in 62.3% of ALS cases, 67.7%
of neurologic controls, 74.7% of nonneurologic controls,
165and 72.6% of GP controls. The differences between ALS
cases and nonneurologic and GP controls were significant
(Table 2).
2 Beghi et al.
Table 1. Characteristics of a Sample of Newly Diagnosed ALS Patients and Age- and Sex-Matched Controls, Italy, 2007–2010
ALS Patients
(n 5 377)
Neurologic
Controls (n 5 377)
Nonneurologic
Controls (n 5 377)
General Practitioner
Controls (n 5 99)
Cancer Controls
(n 5 7,057)
No. % No. % No. % No. % No. %
Female sex 146 38.7 146 38.7 146 38.7 36 36.4 3,109 44.1
Age, years
<65 158 41.9 174 46.2 167 44.3 53 53.5 NAa NA
65–74 149 39.5 125 33.2 137 36.3 29 29.3 NA NA
>74 70 18.6 78 20.7 73 19.4 17 17.2 NA NA
Physical activity (ever) 233 61.8 241 63.9 271** 71.9 79*** 79.8 NA NA
Education, years
<5 20 5.3 31 8.2 22 5.8 1 1.1 2,624b 37.2
5–7 127 33.7 124 32.9 134 35.5 19 20.4
8–12 124 32.9 118 31.3 103 27.3 32 34.4 2,140 30.3
13–17 81 21.5 77 20.4 87 23.1 27 29.0 2,293 32.5
18 25 6.6 27 7.2 31 8.2 14 15.1
Smoking (ever) 174 46.2 186 49.3 201* 53.3 53 53.5 3,929*** 55.7
Alcohol drinking (ever) 166 44.0 172 45.6 204** 54.1 55* 55.5 NA NA
Interviewee
Patient 282 74.8 308* 81.7 311* 82.5 99*** 100.0 NA NA
Surrogate 95 25.2 69 18.3 66 17.5 0 0.0 NA NA
Abbreviations: ALS, amyotrophic lateral sclerosis; NA, not available.
* P < 0.05; **P < 0.01; ***P < 0.001 (compared with ALS patients).
a Among cancer cohort controls, 2,010 (28.5%) were under age 50 years, 2,122 (30.1%) were aged 50–59 years, 2,191 (31.1%) were aged
60–69 years, and 734 (10.4%) were aged 70 years or more.
b For cancer controls, years of education were categorized as <8, 8–12, and 13.
Table 2. Coffee Consumption Among Newly Diagnosed ALS Patients and Age- and Sex-Matched Controls, Italy, 2007–2010
Coffee Consumption
Variable
ALS Patients*
(n 5 324)
Neurologic
Controls* (n 5 362)
Nonneurologic
Controls* (n 5 368)
General Practitioner
Controls (n 5 99)
Cancer Controls
(n 5 7,057)
No. % No. % No. % No. % No. %
Statusa
Ever 242 74.7 291 80.4 315*** 85.6 88** 88.9 6,068*** 86.0
Never 82 25.3 71 19.6 53 14.4 11 11.1 989 14.0
Duration, years
0 82 25.5 71 19.6 53 14.4 11 11.6 NA NA
0.5–30 39 12.1 46 12.7 40 10.9 15* 15.8 NA NA
31–50 124 38.5 151 41.7 160** 43.5 52*** 54.7 NA NA
>50 77 23.9 94 26.0 115*** 31.2 17 17.9 NA NA
Not specified 2 4
History
Never 82 25.3 71 19.6 53 14.4 11 11.5 NA NA
Former 47 14.5 37 10.2 34 9.2 6 6.3 NA NA
Current 195 60.2 254* 70.2 281*** 76.4 79*** 82.3 NA NA
Not specified 3
Abbreviations: ALS, amyotrophic lateral sclerosis; NA, not available.
* P < 0.05; **P < 0.01; ***P < 0.001 (compared with ALS patients).
a Daily consumption for at least 6 months during the participant’s entire lifetime. Information on coffee consumption status was missing for
53 ALS patients, 15 neurologic controls, and 9 nonneurologic controls.
Coffee Consumption and Risk of ALS 3
The odds for any coffee exposure were 20%–60% lower
among cases than among controls, a significant difference
170 (Table 3). An inverse correlation in the duration of coffee
intake was also found between ALS patients and each control
group, but no detectable trends. Current coffee drinkers were
significantly fewer among ALS cases than among neurologic,
nonneurologic, and GP controls. Former coffee drinkers
175 did not differ from nondrinkers (Table 3). However, because
28 ALS patients (59.6%) stopped drinking coffee after onset
of the disease, we repeated our analyses after excluding cases
and controls who stopped consuming coffee after disease
onset. In these cases, the odds for exposure among ALS
180 patients decreased to 0.8 in comparison with neurologic con-
trols, 0.7 for nonneurologic controls, and 0.5 for GP controls,
approaching those of current drinkers (see Web Table 1, which
appears on the Journal’s Web site (http://aje.oxfordjournals.
org/)). The mean age at onset of ALS symptoms among cur-
185 rent coffee drinkers was 63.4 years (standard deviation, 11.3),
as compared with 62.6 years (standard deviation, 13.0) among
nondrinkers, a nonsignificant difference.
The proportion of proxy responders was higher for ALS
patients than for the control groups and may have introduced
190 the potential for differential misclassification, with under-
estimates of coffee intake for some cases. Therefore, we
repeated the multivariate analyses after excluding proxy re-
spondents. The findings were virtually unchanged for overall
coffee intake and history of consumption, but a trend was
195 apparent for duration of exposure when comparing ALS
patients with hospital controls (see Web Table 2).
The independent contributions of tobacco and alcohol (the
most important confounders of coffee intake) and of all of
the other variables included in the logistic regression models
200 are depicted in Web Table 3. The direction of the effect of
coffee exposure among ALS patients was confirmed when
current coffee drinkers and nondrinkers were compared
across different demographic and clinical variables (see Web
Table 4).
205DISCUSSION
In this case-control study, we found that coffee intake was
less frequent and prolonged among patients with ALS than
in different groups of patients with other clinical conditions
(not associated with ALS or coffee exposure) or healthy
210persons. The robustness of the association was confirmed by
the consistency of the findings and, to some extent, by the
duration of exposure.
The data cannot be explained by the use of hospital controls
(who might have reported higher-than-expected exposure to
215caffeine) because the proportions of coffee drinkers were
similar among hospital controls and healthy controls. In ad-
dition, differences reflecting sociocultural habits in cases and
controls are unlikely, because coffee consumption is fairly
uniform in Italy. The possibility of reverse causation can
220also be excluded because, as indicated in Table 2, duration
of coffee consumption was 30 years or longer in a lower
proportion of ALS cases than in the control groups. This is
normally a long period in a person’s life, almost inevitably
preceding the biologic onset of the disease. The inverse
225association between coffee intake and ALS could even be
explained by smoking or alcohol consumption.
The absence of a true gradient is notable, as only current
coffee drinkers seemed to have a lower risk of ALS, while
the risk in former drinkers overlapped that of the general
230population. However, this risk decreased when we excluded
Table 3. Odds Ratios for ALS According to Category of Coffee Consumption in Multivariate Analysis, Italy,
2007–2010a
Coffee Consumption
Model
ALS Patients vs.
Neurologic
Controls
ALS Patients vs.
Nonneurologic
Controls
ALS Patients vs.
General Practitioner
Controls
OR 95% CI OR 95% CI OR 95% CI
Model 1: statusb
Never 1 1 1
Ever 0.7 0.5, 1.1 0.6 0.4, 0.8 0.4 0.2, 0.9
Model 2: duration, years
0 1 1 1
0.5–30 0.7 0.4, 1.3 0.7 0.4, 1.4 0.4 0.1, 1.0
31–50 0.7 0.5, 1.1 0.6 0.4, 0.9 0.4 0.2, 0.7
>50 0.8 0.5, 1.3 0.5 0.3, 0.8 0.8 0.3, 2.0
Model 3: history
Never 1 1 1
Former 1.1 0.7, 2.0 1.0 0.6, 1.7 1.2 0.4, 3.5
Current 0.7 0.5, 1.0 0.5 0.3, 0.7 0.4 0.2, 0.8
Abbreviations: ALS, amyotrophic lateral sclerosis; CI, confidence interval; OR, odds ratio.
a Odds ratios were adjusted for age, sex, exercise, smoking, alcohol drinking, education, and interviewee.
b Daily consumption for at least 6 months during the participant’s entire lifetime.
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cases and controls who stopped drinking coffee after onset
of the disease and approached the level in current drinkers
(see Web Table 1).
To our knowledge, there are no published reports on the
235 association between consumption of caffeinated beverages
or intake of prescription medications and ALS risk. The only
article on diet in ALS that mentioned coffee intake focused
on decaffeinated coffee, which was associated with a higher
risk of ALS (9). However, in that same study, Ascherio
240 et al. (9) found that high consumption of tea, which also
contains caffeine, was associated with a lower risk of ALS.
Epidemiologic studies have shown a positive correla-
tion between dietary caffeine intake and reduced risk of
Parkinson’s disease, another neurodegenerative disease with
245 links to ALS (10–12). In keeping with these observations,
the neurotoxic effect exerted by 1-methyl-4-phenyl-1,2,3,
6-tetrahydropyridine on dopaminergic neurons was reduced
by caffeine and its metabolites (13, 14). Pooled estimates
have also shown that coffee consumption is inversely asso-
250 ciated with the risk of Alzheimer’s disease (15). In a study
of aged mice with Alzheimer’s disease, caffeine reversed
cognitive impairment and lowered brain amyloid-b levels (16).
Caffeine has antioxidant properties (17, 18), which may
counteract the oxidative stress associated with aging and risk
255 of developing neurodegenerative diseases.
Caffeine has multiple targets in the brain—for example,
adenosine, ryanodine, and c-aminobutyric acid a receptors,
and cyclic nucleotide phosphodiesterase isoenzymes (19).
Its action on adenosine A2a receptors may explain the
260 psychomotor stimulant effect, mediated by dopaminergic
mechanisms. In an animal model of ALS, coffee was found
to increase antioxidant enzyme capacity in the brains of
male G39A mice, improving motor performance (20).
High calcium ion concentrations are harmful to motor
265 neurons in persons with ALS (21), and caffeine can im-
prove the sensitivity of ryanodine channels to calcium ions.
Ryanodine binding sites are also involved in intracellular
calcium ion signaling in the Golgi complex in neurons (22).
This could be relevant, because derangement of the Golgi
270 complex is one probable cause of some forms of progressive
neuronal degeneration, such as Alzheimer’s disease and ALS.
A caffeine derivative known as LM11A-24 seems to protect
degenerating motor neurons (23). In electrophysiologic studies
on healthy human muscle, caffeine had positive effects on
275 muscle and lower and upper motor neuron excitability (24).
This study has some strengths and several limitations. The
major strength is the representativeness and size of the ALS
sample, which included a large cohort of patients with newly
diagnosed disease residing in the areas where the population-
280 based registries were located. A second strength is the con-
sistency of our findings across different controls, including
population-based controls who were fairly representative
of the Italian general population. A third strength is the
unexpected observation, which reduced the probability of
285 interview or interviewer bias. A fourth strength is the biologic
mechanisms in support of caffeine’s action and the fairly
robust epidemiologic evidence of a similar association in
patients with Parkinson’s disease and Alzheimer’s disease,
two neurodegenerative disorders sharing some pathologic
290 features with ALS. A fifth strength is the confirmation of our
results even among strata of several variables that could act
as potential confounders.
The main limitation is the nonstandardized collection of
data on coffee consumption, which was used here as a con-
295founding variable. Although we defined coffee drinkers as
those who had consumed coffee daily for at least 6 months
in their lifetime, the crude classification of coffee intake
(ever vs. never) was weak. A second limitation is the use of
controls from different sources, which may have affected the
300reported rates, and the different definitions of exposure. This
may explain the higher proportion of smokers among our
controls, which seems to contrast with the results of other
studies (25). This may also be true for the cancer cohort
controls, in whom intake was calculated as number of cups
305per day. A third limitation is the higher proportion of proxy
responders among ALS patients than in all of the control
groups. However, information bias can be excluded, because
the inverse association remained when the analyses were
limited to index subjects’ interviews. A fourth limitation is
310that hospital controls might have a number of clinical condi-
tions that benefit from caffeine intake. Although this possibility
cannot be entirely excluded, it is unlikely considering the
range of diseases leading to hospitalization. In addition, several
neurologic controls had had strokes, and several nonneurologic
315controls had cardiovascular disorders, which have been as-
sociated with coffee consumption. A fifth limitation is the
unknown numbers of cases and controls using decaffeinated
coffee. However, no important effect on our estimates is
likely, because few people in Italy drink decaffeinated coffee
320(4% in the cancer control group) (8). A sixth limitation is that
this is the first observation of an association between coffee
intake and ALS and, as such, it needs confirmation. In addi-
tion, only caffeine was discussed as a possible neuroprotective
agent. Other components of coffee need proper assessment for
325a full evaluation of the biologic plausibility of the purported
association between caffeine intake and risk of ALS.
Further studies are now being planned to investigate the
possible protective association of caffeine and/or other coffee
ingredients with motor neuron diseases using an ad hoc
330design and a predefined model for data collection.
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